LV12832B - Paņēmiens herpesa zostervīrusa infekcijas novēršanai un ar varicellu saistītas pēcherpesa neiralģijas atvieglošanai - Google Patents

Paņēmiens herpesa zostervīrusa infekcijas novēršanai un ar varicellu saistītas pēcherpesa neiralģijas atvieglošanai

Info

Publication number
LV12832B
LV12832B LVP-02-40A LV020040A LV12832B LV 12832 B LV12832 B LV 12832B LV 020040 A LV020040 A LV 020040A LV 12832 B LV12832 B LV 12832B
Authority
LV
Latvia
Prior art keywords
vzv
risk
varicella
individuals
responder cell
Prior art date
Application number
LVP-02-40A
Other languages
English (en)
Latvian (lv)
Other versions
LV12832A (en
Inventor
Gary B. Calandra
Philip J. PROVOST
Myron J. LEVIN
Jo C. WHITE
Original Assignee
Merck & Co. Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25435290&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LV12832(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck & Co. Inc. filed Critical Merck & Co. Inc.
Publication of LV12832A publication Critical patent/LV12832A/en
Publication of LV12832B publication Critical patent/LV12832B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/25—Varicella-zoster virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Exchange Systems With Centralized Control (AREA)
LVP-02-40A 1992-07-17 2002-03-15 Paņēmiens herpesa zostervīrusa infekcijas novēršanai un ar varicellu saistītas pēcherpesa neiralģijas atvieglošanai LV12832B (lv)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US91514192A 1992-07-17 1992-07-17

Publications (2)

Publication Number Publication Date
LV12832A LV12832A (en) 2002-05-20
LV12832B true LV12832B (lv) 2002-09-20

Family

ID=25435290

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-02-40A LV12832B (lv) 1992-07-17 2002-03-15 Paņēmiens herpesa zostervīrusa infekcijas novēršanai un ar varicellu saistītas pēcherpesa neiralģijas atvieglošanai

Country Status (15)

Country Link
US (2) US5997880A (es)
EP (1) EP0651789B2 (es)
JP (3) JP4562812B2 (es)
AT (1) ATE210722T1 (es)
AU (1) AU687355B2 (es)
CA (1) CA2139515C (es)
CY (1) CY2286B1 (es)
DE (2) DE69331322T3 (es)
DK (1) DK0651789T4 (es)
ES (1) ES2165367T5 (es)
LU (1) LU91287I2 (es)
LV (1) LV12832B (es)
NL (1) NL300246I2 (es)
PT (1) PT651789E (es)
WO (1) WO1994002596A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0504436D0 (en) 2005-03-03 2005-04-06 Glaxosmithkline Biolog Sa Vaccine
BRPI0906527A2 (pt) * 2008-04-04 2016-09-06 3Mm Innovative Properties Company aparelho para aplicação de bandagens em ferimentos e bandagem médica
UA112970C2 (uk) * 2010-08-05 2016-11-25 Мерк Шарп Енд Доме Корп. Інактивований вірус вітряної віспи, спосіб його одержання і застосування
WO2014043189A1 (en) 2012-09-14 2014-03-20 The Regents Of The University Of Colorado, A Body Corporate Conditionally replication deficient herpes viruses and use thereof in vaccines
WO2015034807A2 (en) 2013-09-05 2015-03-12 Merck Sharp & Dohme Corp. Methods of immunization with varicella zoster virus antigen
CN108778289B (zh) 2015-11-06 2020-11-17 佐剂技术公司 三萜皂苷类似物
CA3061205A1 (en) 2017-04-25 2018-11-01 Memorial Sloan Kettering Cancer Center Triterpene saponin analogues
BR112022017852A2 (pt) 2020-03-09 2022-11-01 Dynavax Tech Corp Vacinas para herpes zoster compreendendo um agonista de tlr9
JP7442386B2 (ja) 2020-05-14 2024-03-04 東京エレクトロン株式会社 基板処理装置

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US376788A (en) * 1888-01-24 strait
US441737A (en) * 1890-12-02 Tapping-machine for stay-bolt holes
JPS5341202B2 (es) * 1974-03-12 1978-11-01
US4000256A (en) * 1975-04-30 1976-12-28 Merck & Co., Inc. Varicella vaccine and process for its preparation
US4008317A (en) * 1975-12-29 1977-02-15 Recherche Et Industrie Therapeutiques (R.I.T.) Varicella-zoster virus vaccine and preparation thereof
US4147772A (en) * 1976-02-03 1979-04-03 Merck & Co., Inc. Vaccine stabilizer
DE2714665A1 (de) * 1977-04-01 1978-10-05 Mayr Anton Praeparat zur behandlung von herpes zoster und anderen herpes-infektionen, sowie verfahren zu seiner herstellung
US4273762A (en) * 1979-12-03 1981-06-16 Merck & Co., Inc. Lyophilization process for live viral compositions
US4337242A (en) * 1980-02-05 1982-06-29 Merck & Co., Inc. Vaccine stabilizer containing L-glutamic acid and L-arginine
US4338335A (en) * 1980-02-05 1982-07-06 Merck & Co., Inc. Vaccine stabilizer containing L-glutamic acid and L-arginine
EP0101200A3 (en) * 1982-07-20 1985-03-06 BIO-COM Inc. Transfer factor for use in treating viral infections
US4769239A (en) * 1984-08-21 1988-09-06 Merck & Co., Inc. Vaccine against varicella-zoster virus
EP0211756A1 (en) * 1985-08-01 1987-02-25 Merck & Co. Inc. Assay for varicella-zoster virus (VZV) antibodies
US4686101A (en) * 1985-08-02 1987-08-11 Merck & Co., Inc. Vaccine against varicella-zoster virus
US4952674A (en) * 1986-05-02 1990-08-28 Merck & Co., Inc. Vaccine against varicella-zoster virus
NZ220645A (en) * 1986-06-20 1989-10-27 Merck & Co Inc Modified varicella-zoster virus and its cultivation
US5024836A (en) * 1987-05-04 1991-06-18 Merck & Co., Inc. Stable lyophilized live herpes virus vaccine
DE69017769T2 (de) * 1989-06-27 1995-07-13 Smithkline Beecham Biologicals S.A., Rixensart Verbindungen.
ES2150906T3 (es) * 1990-10-04 2000-12-16 Res Corp Technologies Inc Antigeno del virus varicella-zoster.

Also Published As

Publication number Publication date
NL300246I2 (nl) 2007-02-01
DE122006000063I1 (de) 2007-05-10
JP2010189420A (ja) 2010-09-02
EP0651789A4 (en) 1996-06-26
DE69331322T3 (de) 2009-10-22
ES2165367T3 (es) 2002-03-16
AU687355B2 (en) 1998-02-26
CA2139515C (en) 2008-12-23
WO1994002596A1 (en) 1994-02-03
US6214354B1 (en) 2001-04-10
LV12832A (en) 2002-05-20
CA2139515A1 (en) 1994-02-03
CY2286B1 (en) 2003-07-04
ATE210722T1 (de) 2001-12-15
JPH07509244A (ja) 1995-10-12
EP0651789B1 (en) 2001-12-12
DK0651789T4 (da) 2009-07-27
JP4562812B2 (ja) 2010-10-13
PT651789E (pt) 2002-05-31
DK0651789T3 (da) 2002-03-11
LU91287I2 (fr) 2007-01-15
JP2004323531A (ja) 2004-11-18
AU4676093A (en) 1994-02-14
DE69331322T2 (de) 2002-08-08
DE69331322D1 (de) 2002-01-24
US5997880A (en) 1999-12-07
EP0651789A1 (en) 1995-05-10
EP0651789B2 (en) 2009-05-20
NL300246I1 (nl) 2007-01-02
ES2165367T5 (es) 2009-08-05

Similar Documents

Publication Publication Date Title
Harrison et al. Modification of immunological responses and clinical disease during topical R-837 treatment of genital HSV-2 infection
Meignier et al. Immunization of experimental animals with reconstituted glycoprotein mixtures of herpes simplex virus 1 and 2: protection against challenge with virulent virus
Russell et al. Cell-mediated immunity to varicella-zoster antigen in acute herpes zoster (shingles)
Santoli et al. Cytotoxic activity and interferon production by lymphocytes from patients with multiple sclerosis.
Gershon et al. Antibody responses to varicella-zoster virus and the role of antibody in host defense
LV12832B (lv) Paņēmiens herpesa zostervīrusa infekcijas novēršanai un ar varicellu saistītas pēcherpesa neiralģijas atvieglošanai
Jordan et al. Cell-mediated immunity to varicella-zoster virus: in vitro lymphocyte responses
Carl et al. Food-borne hepatitis A: recommendations for control
Glorioso et al. Immune interactions with cells infected with herpes simplex virus: antibodies to radioiodinated surface antigens
Patterson-Bartlett et al. Phenotypic and functional characterization of ex vivo T cell responses to the live attenuated herpes zoster vaccine
Rabson et al. Depressed neutrophil motility in patients with recurrent herpes simplex virus infections: in vitro restoration with levamisole
Meignier et al. Colonization of murine ganglia by a superinfecting strain of herpes simplex virus
Pauli et al. Immunoprecipitation of herpes simplex virus type 1 antigens with different antisera and human cerebrospinal fluids
Kumagai et al. Development and characteristics of the cellular immune response to infection with varicella-zoster virus
Baker et al. Resistance of female mice to vaginal infection induced by Herpesvirus hominis type 2: effects of immunization with Mycobacterium bovis, intravenous injection of specific Herpesvirus hominis type 2 antiserum, and a combination of these procedures
Gutekunst et al. Humoral and cellular immune responses in swine after vaccination with inactivated pseudorabies virus
Hata Skin test with varicella-zoster virus antigen on herpes zoster patients
Cabasso et al. Correlation of B virus and herpes simplex virus antibodies in human sera
Smith et al. Effect of cross-immunization on monotypic antibody responses to herpes simplex virus types 1 and 2
Takahashi et al. Immunization of the elderly to boost immunity against varicella-zoster virus (VZV) as assessed by VZV skin test reaction
Gershon Viral vaccines of the future
OA09653A (en) Rubella peptides
Ten Napel et al. Cytomegalovirus-directed lymphocyte reactivity in healthy adults tested by a CMV-induced lymphocyte transformation test
Gold et al. Chronic-dose acyclovir to suppress frequently recurring genital herpes simplex virus infection: effect on antibody response to herpes simplex virus type 2 proteins
Arias-Santiago et al. Cold urticaria associated with Epstein-Barr virus mononucleosis